Researchers tracking peptide clinical trial news should note these ongoing studies: NAFLD/NASH Research The most significant ongoing research involves tesamorelin NAFLD (nonalcoholic fatty liver disease) studies: Rationale: Tesamorelin's documented reduction of visceral adipose tissue may benefit hepatic fat accumulation Key studies: Multiple trials have evaluated tesamorelin's effects on liver fat content in HIV and non-HIV populations Published findings (2024-2025): Studies in JAMA Internal Medicine and Hepatology have documented reductions in hepatic fat fraction Latest tesamorelin research 2025-2026: Recent studies from 2024-2026 continue to evaluate hepatic fat reduction in non-HIV NAFLD/MASH populations, with new analyses examining long-term durability of VAT reduction Cognitive Function Studies Research has explored tesamorelin's effects on cognitive function, particularly in HIV patients where cognitive impairment is common: GH/IGF-1 axis involvement in neuroprotection Studies examining memory and executive function outcomes Ongoing investigation of mechanisms beyond metabolic effects Body Composition Research As a tesamorelin growth hormone analog, research continues into body composition effects: Trunk fat reduction Lipid profile improvements Metabolic marker changes ClinicalTrials.gov Listings Researchers can search ClinicalTrials.gov for "tesamorelin" to find current and completed studies
As demand for peptide products continues to grow, organizations and individual buyers increasingly look for suppliers capable of supporting both immediate purchasing needs and long-term sourcing objectives
Safe for most skin types, its a popular choice for those seeking effective, non-surgical skin rejuvenation
If the water volume is correct, refrigerate the vial for 10 to 15 minutes, then try rolling again
However, no significant difference was evident in transcription level of TGF between groups at different timepoints and within groups over time
